Andrew Johns

559 total citations
33 papers, 243 citations indexed

About

Andrew Johns is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andrew Johns has authored 33 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Andrew Johns's work include Cancer Immunotherapy and Biomarkers (15 papers), Colorectal Cancer Treatments and Studies (7 papers) and Renal cell carcinoma treatment (6 papers). Andrew Johns is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Colorectal Cancer Treatments and Studies (7 papers) and Renal cell carcinoma treatment (6 papers). Andrew Johns collaborates with scholars based in United States and United Kingdom. Andrew Johns's co-authors include Carolyn J. Presley, Gregory A. Otterson, Dwight H. Owen, Kari Kendra, Mingjia Li, Madison Grogan, Marium Husain, J. César Félix‐Brasdefer, Daniel Spakowicz and Lai Wei and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Andrew Johns

28 papers receiving 240 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Johns United States	10	163	61	46	27	23	33	243
Susann Theile Denmark	9	207 1.3×	55 0.9×	71 1.5×	16 0.6×	18 0.8×	26	303
Caterina Accettura Italy	7	104 0.6×	40 0.7×	24 0.5×	22 0.8×	35 1.5×	14	170
Jayeshkumar Patel United States	10	47 0.3×	20 0.3×	79 1.7×	21 0.8×	27 1.2×	21	221
Elles M. Screever Netherlands	10	52 0.3×	18 0.3×	40 0.9×	23 0.9×	9 0.4×	16	201
Susan Jin United States	7	73 0.4×	29 0.5×	29 0.6×	9 0.3×	11 0.5×	11	267
Jamal Misleh United States	7	93 0.6×	63 1.0×	48 1.0×	4 0.1×	25 1.1×	24	204
Hussein Awada United States	9	64 0.4×	18 0.3×	87 1.9×	99 3.7×	22 1.0×	41	223
B.E. van den Borne Netherlands	6	103 0.6×	99 1.6×	32 0.7×	11 0.4×	10 0.4×	10	210
Jennifer Kherani United States	10	113 0.7×	104 1.7×	65 1.4×	10 0.4×	12 0.5×	19	241
Gökhan Uçar Türkiye	11	136 0.8×	83 1.4×	28 0.6×	5 0.2×	44 1.9×	42	254

Countries citing papers authored by Andrew Johns

Since Specialization

Citations

This map shows the geographic impact of Andrew Johns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Johns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Johns more than expected).

Fields of papers citing papers by Andrew Johns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Johns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Johns. The network helps show where Andrew Johns may publish in the future.

Co-authorship network of co-authors of Andrew Johns

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Johns. A scholar is included among the top collaborators of Andrew Johns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Johns. Andrew Johns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilson, Neil, Devaki Shilpa Surasi, Tharakeswara Bathala, et al.. (2025). Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma.. Journal of Clinical Oncology. 43(5_suppl). 558–558.

Johns, Andrew, Matthew T. Campbell, Ahmet Murat Aydın, et al.. (2024). Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. Journal of Clinical Medicine. 13(12). 3436–3436.

Johns, Andrew, Matthew T. Campbell, Andrew W. Hahn, et al.. (2024). Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. The Oncologist. 29(7). 589–595. 3 indexed citations

Alhalabi, Omar, Matthew T. Campbell, Guillermo Alonso, et al.. (2024). Abstract 7523: An integrated analysis of radiologic and pathological responses in patients with metastatic renal cell carcinoma who presented with primary renal tumor in situ and received first-line nivolumab plus ipilimumab followed by cytoreductive nephrectomy. Cancer Research. 84(6_Supplement). 7523–7523.

Wang, Emily, Andrew Johns, Matthew T. Campbell, et al.. (2024). Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. European Urology Focus. 11(1). 150–158. 2 indexed citations

Johns, Andrew, Matthew T. Campbell, Zita Dubauskas Lim, et al.. (2024). Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 42(4_suppl). 419–419.

Johns, Andrew, Lai Wei, Madison Grogan, et al.. (2023). Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. The Oncologist. 28(8). e625–e632. 7 indexed citations

Johns, Andrew, Lai Wei, Madison Grogan, et al.. (2023). Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy. Cancer Immunology Immunotherapy. 72(7). 2005–2013. 7 indexed citations

Johns, Andrew, Matthew T. Campbell, Pavlos Msaouel, et al.. (2023). CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).. Journal of Clinical Oncology. 41(16_suppl). 4597–4597. 1 indexed citations

10.

Tinoco, Gabriel, Songzhu Zhao, Lai Wei, et al.. (2022). Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. Journal of Cancer Research and Clinical Oncology. 149(5). 2235–2242. 25 indexed citations

11.

Zhao, Songzhu, Mingjia Li, Sandip H. Patel, et al.. (2021). Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunology Immunotherapy. 71(5). 1157–1165. 24 indexed citations

12.

Zhang, Shijun, Chien‐Wei Chiang, Gregory A. Otterson, et al.. (2021). Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunology Immunotherapy. 70(10). 2761–2769. 10 indexed citations

13.

Johns, Andrew, Lai Wei, Madison Grogan, et al.. (2021). Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. Journal of Geriatric Oncology. 12(5). 813–819. 27 indexed citations

14.

Husain, Marium, Menglin Xu, Sandipkumar Patel, et al.. (2021). Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.. Journal of Clinical Oncology. 39(15_suppl). 2633–2633. 9 indexed citations

15.

Li, Mingjia, Daniel Spakowicz, Songzhu Zhao, et al.. (2020). Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunology Immunotherapy. 69(11). 2403–2408. 12 indexed citations

16.

Johns, Andrew, Desmond M. D’Souza, Terence M. Williams, et al.. (2020). Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy. Clinical Lung Cancer. 21(4). e243–e245. 1 indexed citations

17.

Qin, Angel, Lai Wei, Sandip H. Patel, et al.. (2019). P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study. Journal of Thoracic Oncology. 14(10). S387–S387. 1 indexed citations

18.

Owen, Dwight H., Jarred Burkart, Sandip H. Patel, et al.. (2018). Immune related adverse events across cancer types: Incidence, risk factors and survival. Annals of Oncology. 29. viii630–viii631. 3 indexed citations

19.

Mendenhall, Charles M., et al.. (2017). Radiotherapy Alone or With Chemotherapy in the Management of Carcinoma of the Supraglottic Larynx. American Journal of Clinical Oncology. 41(9). 894–897. 1 indexed citations

20.

Johns, Andrew, et al.. (2010). Talent Is Not Enough. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact